悪性血液疾患に関する世界のパイプライン動向および分析

Abstract

Introduction

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

• Investigator - Includes 212 investigators and partners
• Drug - Includes 237 “active” drugs
• Sub-indication - Includes 11 sub-indications
• Developmental stage - Includes 8 developmental stages
• Compound type - Includes 21 different compounds types
• Targeted therapy strategy - Includes 5 different targeted therapy strategies
• Target - Includes 97 different protein targets
• Signaling pathway - Includes 18 different signaling pathways

All of above “factors” are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each “factor” included in this cutting edge analysis.

Table of Contents

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS

• 2.1 LIST OF FIGURES
• 2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

• 4.1 DRUG PIPELINE BY LEUKEMIA
• 4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

• 5.1 PURSUED TARGETS IN LEUKEMIA
• 5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS

• 6.1 OVERVIEW OF COMPOUNDS
• 6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.5 LEUKEMIA BY COMPOUND TYPES
• 6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

• 7.1 TARGETED THERAPIES IN LEUKEMIA
• 7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

• 8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
• 8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

• 9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
  • 9.1.1 DESCRIPTION OF PATHWAY
  • 9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
  • 9.2.1 DESCRIPTION OF PATHWAY
  • 9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.3 B CELL RECEPTOR SIGNALING PATHWAY
  • 9.3.1 DESCRIPTION OF PATHWAY
  • 9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.4 EGFR1 SIGNALING PATHWAY
  • 9.4.1 DESCRIPTION OF PATHWAY
  • 9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.5 ID SIGNALING PATHWAY
  • 9.5.1 DESCRIPTION OF PATHWAY
  • 9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.6 IL-1 SIGNALING PATHWAY
  • 9.6.1 DESCRIPTION OF PATHWAY
  • 9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.7 IL-2 SIGNALING PATHWAY
  • 9.7.1 DESCRIPTION OF PATHWAY
  • 9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.8 IL-3 SIGNALING PATHWAY
  • 9.8.1 DESCRIPTION OF PATHWAY
  • 9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.9 IL-4 SIGNALING PATHWAY
  • 9.9.1 DESCRIPTION OF PATHWAY
  • 9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.10 IL-5 SIGNALING PATHWAY
  • 9.10.1 DESCRIPTION OF PATHWAY
  • 9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.11 IL-6 SIGNALING PATHWAY
  • 9.11.1 DESCRIPTION OF PATHWAY
  • 9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.12 IL-7 SIGNALING PATHWAY
  • 9.12.1 DESCRIPTION OF PATHWAY
  • 9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.13 KIT RECEPTOR SIGNALING PATHWAY
  • 9.13.1 DESCRIPTION OF PATHWAY
  • 9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.14 NOTCH SIGNALING PATHWAY
  • 9.14.1 DESCRIPTION OF PATHWAY
  • 9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.15 T CELL RECEPTOR SIGNALING PATHWAY
  • 9.15.1 DESCRIPTION OF PATHWAY
  • 9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
  • 9.16.1 DESCRIPTION OF PATHWAY
  • 9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.17 TNF-ALPHA SIGNALING PATHWAY
  • 9.17.1 DESCRIPTION OF PATHWAY
  • 9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.18 WNT SIGNALING PATHWAY
  • 9.18.1 DESCRIPTION OF PATHWAY
  • 9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

• 11.1 LIABILITY
• 11.2 COMPLETENESS

List of Figures

• Figure 1: The Hematological Cancer Developmental Pipeline
• Figure 2: The Leukemia Developmental Pipeline
• Figure 3: The Lymphoma Developmental Pipeline
• Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
• Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
• Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
• Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
• Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
• Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
• Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
• Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
• Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
• Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
• Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
• Figure 15: Angiogenesis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 16: Apoptosis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 17: Protein Kinase Inhibitors - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 18: Vaccines - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 19: Angiogenesis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 20: Apoptosis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 21: Protein Kinase Inhibitor - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 22: Vaccines - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
• Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
• Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
• Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
• Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

List of Tables

• Table 1: List of Active Players in the Field of Hematological Malignancies
• Table 2: The Leukemia Developmental Pipeline
• Table 3: The Lymphoma Developmental Pipeline
• Table 4: List of Pursued Protein Targets in Hematological Cancers
• Table 5: Hematological Cancer Targets by Investigator and Drug
• Table 6: Pursued Targets by Sub-indications of Leukemia
• Table 7: Pursued Targets by Sub-indications of Lymphoma
• Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
• Table 9: List of Biological Compounds
• Table 10: List of Chemical Compounds
• Table 11: List of Natural Compounds
• Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
• Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
• Table 14: List of Targeted Therapies in Leukemia
• Table 15: List of Targeted Therapies in Lymphoma
• Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
• Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
• Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
• Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
• Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
• Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
• Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
• Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
• Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
• Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
• Table 26: Targets Linking Drugs to the ID Signaling Pathway
• Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
• Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
• Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
• Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
• Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
• Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
• Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
• Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
• Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
• Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
• Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
• Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
• Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
• Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
• Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
• Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
• Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
• Table 44: Targets Linking Drugs to theNotch Signaling Pathway
• Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
• Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
• Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
• Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
• Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
• Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
• Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
• Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
• Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway